VIDEO: Segmenting the Radiology Artificial Intelligence Market by Function

"Today, we live in that quadrant of things humans can do and humans are supervising," Dreyer explained. "That is all the [U.S. Food and Drug Administration (FDA)] approved AI stuff that we see today." He said the next step is for AI to move into the realm of superhuman work, such as measuring 1,000 lymph nodes at once, or to make a risk prediction about future events in the next two years based on the patient's prior 40 images, because it looks like a million other patients' scans. Dreyer said the FDA is in discussions with vendors on fully autonomous AI for radiology applications, but the agency wants to see controls built into the software.